Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine.

Bing WanLu QinWeihong MaHe Wang

Published in: Infectious agents and cancer (2022)

We successfully constructed the HPV16/18/58 trivalent therapeutic adenovirus vaccine AD-HPV16/18/58 mE6E7. The AD-HPV16/18/58 mE6E7 adenovirus vaccine can protect immunized mice to a certain extent from TC-1, U14/LV-HPV18 E6E7 and U14/LV-HPV58 E6E7 cells, which contain HPV16, 18 and 58 E6 and/or E7 genes, respectively.

Keyphrases

high grade
cervical cancer screening
gene expression
metabolic syndrome
wastewater treatment
gene therapy
cell death
wild type